APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Neuropathic Pain Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Diabetic Neuropathic Pain Drug Market Analysis and Forecast 2026-2032

26 December 2025202 pages

Choose your research edition.

Industry ResearchDiabetic Neuropathic Pain Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Neuropathic Pain Drug Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Diabetic Neuropathic Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Neuropathic Pain Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Neuropathic Pain Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Diabetic Neuropathic Pain Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Diabetic Neuropathic Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Diabetic Neuropathic Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Diabetic Neuropathic Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Diabetic Neuropathic Pain Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Diabetic Neuropathic Pain Drug include Eli Lilly and Company, Astellas Pharma Inc., AstraZeneca Plc, Theravasc, Inc., Sphaera Pharma Pvt. Ltd., Relmada Therapeutics, Inc., RAPID Pharmaceuticals AG, Pharmaleads and Novaremed, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Diabetic Neuropathic Pain Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Diabetic Neuropathic Pain Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Diabetic Neuropathic Pain Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Diabetic Neuropathic Pain Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Diabetic Neuropathic Pain Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Diabetic Neuropathic Pain Drug sales, projected growth trends, production technology, application and end-user industry.

Diabetic Neuropathic Pain Drug Segment by Company

Eli Lilly and Company

Astellas Pharma Inc.

AstraZeneca Plc

Theravasc, Inc.

Sphaera Pharma Pvt. Ltd.

Relmada Therapeutics, Inc.

RAPID Pharmaceuticals AG

Pharmaleads

Novaremed

Mertiva AB

Lohocla Research Corporation

Laboratorios Del Dr. Esteve S.A.

Immune Pharmaceuticals Inc.

Hydra Biosciences, Inc.

Glenmark Pharmaceuticals Ltd.

Dong-A Socio Group

Daiichi Sankyo Company, Limited

Boehringer Ingelheim GmbH

BioDelivery Sciences International, Inc.

Diabetic Neuropathic Pain Drug Segment by Type

AZD-5213

E-52862

GERPOOI

GRC-17536

Filgrastim

Duloxetine Hydrochloride DR

Clonidine Hydrochloride

Others

Diabetic Neuropathic Pain Drug Segment by Application

Clinic

Hospital

Others

Diabetic Neuropathic Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Neuropathic Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Neuropathic Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Neuropathic Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Diabetic Neuropathic Pain Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Diabetic Neuropathic Pain Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diabetic Neuropathic Pain Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. AZD-5213 Major Manufacturers Table 3. E-52862 Major Manufacturers Table 4. GERPOOI Major Manufacturers Table 5. GRC-17536 Major Manufacturers Table 6. Filgrastim Major Manufacturers Table 7. Duloxetine Hydrochloride DR Major Manufacturers Table 8. Clonidine Hydrochloride Major Manufacturers Table 9. Others Major Manufacturers Table 10. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 11. Clinic Major Manufacturers Table 12. Hospital Major Manufacturers Table 13. Others Major Manufacturers Table 14. Diabetic Neuropathic Pain Drug Industry Trends Table 15. Diabetic Neuropathic Pain Drug Industry Drivers Table 16. Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges Table 17. Diabetic Neuropathic Pain Drug Industry Restraints Table 18. Global Diabetic Neuropathic Pain Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Diabetic Neuropathic Pain Drug Revenue by Region (2021-2026) & (US$ Million) Table 20. Global Diabetic Neuropathic Pain Drug Revenue by Region (2027-2032) & (US$ Million) Table 21. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2021-2026) Table 22. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2027-2032) Table 23. Global Diabetic Neuropathic Pain Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 24. Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026) & (W Units) Table 25. Global Diabetic Neuropathic Pain Drug Sales by Region (2027-2032) & (W Units) Table 26. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2021-2026) Table 27. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2027-2032) Table 28. Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2021-2026) Table 30. Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2021-2026) Table 32. Global Diabetic Neuropathic Pain Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 33. Global Diabetic Neuropathic Pain Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global Diabetic Neuropathic Pain Drug Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global Diabetic Neuropathic Pain Drug Manufacturers, Product Type & Application Table 36. Global Diabetic Neuropathic Pain Drug Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global Diabetic Neuropathic Pain Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Diabetic Neuropathic Pain Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 41. Global Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 42. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2021-2026) Table 43. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2027-2032) Table 44. Global Diabetic Neuropathic Pain Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 45. Global Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 46. Global Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 47. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2021-2026) Table 48. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2027-2032) Table 49. Global Diabetic Neuropathic Pain Drug Price by Type (2021-2026) & (US$/Unit) Table 50. Global Diabetic Neuropathic Pain Drug Price by Type (2027-2032) & (US$/Unit) Table 51. Global Diabetic Neuropathic Pain Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 53. Global Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 54. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2021-2026) Table 55. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2027-2032) Table 56. Global Diabetic Neuropathic Pain Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 57. Global Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 58. Global Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 59. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2021-2026) Table 60. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2027-2032) Table 61. Global Diabetic Neuropathic Pain Drug Price by Application (2021-2026) & (US$/Unit) Table 62. Global Diabetic Neuropathic Pain Drug Price by Application (2027-2032) & (US$/Unit) Table 63. Eli Lilly and Company Company Information Table 64. Eli Lilly and Company Business Overview Table 65. Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio Table 67. Eli Lilly and Company Recent Development Table 68. Astellas Pharma Inc. Company Information Table 69. Astellas Pharma Inc. Business Overview Table 70. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 72. Astellas Pharma Inc. Recent Development Table 73. AstraZeneca Plc Company Information Table 74. AstraZeneca Plc Business Overview Table 75. AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio Table 77. AstraZeneca Plc Recent Development Table 78. Theravasc, Inc. Company Information Table 79. Theravasc, Inc. Business Overview Table 80. Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 82. Theravasc, Inc. Recent Development Table 83. Sphaera Pharma Pvt. Ltd. Company Information Table 84. Sphaera Pharma Pvt. Ltd. Business Overview Table 85. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 87. Sphaera Pharma Pvt. Ltd. Recent Development Table 88. Relmada Therapeutics, Inc. Company Information Table 89. Relmada Therapeutics, Inc. Business Overview Table 90. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 92. Relmada Therapeutics, Inc. Recent Development Table 93. RAPID Pharmaceuticals AG Company Information Table 94. RAPID Pharmaceuticals AG Business Overview Table 95. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio Table 97. RAPID Pharmaceuticals AG Recent Development Table 98. Pharmaleads Company Information Table 99. Pharmaleads Business Overview Table 100. Pharmaleads Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio Table 102. Pharmaleads Recent Development Table 103. Novaremed Company Information Table 104. Novaremed Business Overview Table 105. Novaremed Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Novaremed Diabetic Neuropathic Pain Drug Product Portfolio Table 107. Novaremed Recent Development Table 108. Mertiva AB Company Information Table 109. Mertiva AB Business Overview Table 110. Mertiva AB Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio Table 112. Mertiva AB Recent Development Table 113. Lohocla Research Corporation Company Information Table 114. Lohocla Research Corporation Business Overview Table 115. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio Table 117. Lohocla Research Corporation Recent Development Table 118. Laboratorios Del Dr. Esteve S.A. Company Information Table 119. Laboratorios Del Dr. Esteve S.A. Business Overview Table 120. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio Table 122. Laboratorios Del Dr. Esteve S.A. Recent Development Table 123. Immune Pharmaceuticals Inc. Company Information Table 124. Immune Pharmaceuticals Inc. Business Overview Table 125. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 127. Immune Pharmaceuticals Inc. Recent Development Table 128. Hydra Biosciences, Inc. Company Information Table 129. Hydra Biosciences, Inc. Business Overview Table 130. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 132. Hydra Biosciences, Inc. Recent Development Table 133. Glenmark Pharmaceuticals Ltd. Company Information Table 134. Glenmark Pharmaceuticals Ltd. Business Overview Table 135. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio Table 137. Glenmark Pharmaceuticals Ltd. Recent Development Table 138. Dong-A Socio Group Company Information Table 139. Dong-A Socio Group Business Overview Table 140. Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio Table 142. Dong-A Socio Group Recent Development Table 143. Daiichi Sankyo Company, Limited Company Information Table 144. Daiichi Sankyo Company, Limited Business Overview Table 145. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio Table 147. Daiichi Sankyo Company, Limited Recent Development Table 148. Boehringer Ingelheim GmbH Company Information Table 149. Boehringer Ingelheim GmbH Business Overview Table 150. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio Table 152. Boehringer Ingelheim GmbH Recent Development Table 153. BioDelivery Sciences International, Inc. Company Information Table 154. BioDelivery Sciences International, Inc. Business Overview Table 155. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio Table 157. BioDelivery Sciences International, Inc. Recent Development Table 158. North America Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 159. North America Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 160. North America Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 161. North America Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 162. North America Diabetic Neuropathic Pain Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 163. North America Diabetic Neuropathic Pain Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 164. North America Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 165. North America Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 166. North America Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 167. North America Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 168. North America Diabetic Neuropathic Pain Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 169. North America Diabetic Neuropathic Pain Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 170. North America Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. North America Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. North America Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. North America Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 174. North America Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 175. North America Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 176. North America Diabetic Neuropathic Pain Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 177. North America Diabetic Neuropathic Pain Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 178. United States Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 179. Canada Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 180. Mexico Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 181. Europe Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 182. Europe Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 183. Europe Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 184. Europe Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 185. Europe Diabetic Neuropathic Pain Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 186. Europe Diabetic Neuropathic Pain Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 187. Europe Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 188. Europe Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 189. Europe Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 190. Europe Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 191. Europe Diabetic Neuropathic Pain Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 192. Europe Diabetic Neuropathic Pain Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 193. Europe Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 194. Europe Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 195. Europe Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 196. Europe Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 197. Europe Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 198. Europe Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 199. Europe Diabetic Neuropathic Pain Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 200. Europe Diabetic Neuropathic Pain Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 201. Germany Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 202. France Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 203. U.K. Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 204. Italy Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 205. Russia Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 206. Spain Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 207. Netherlands Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 208. Switzerland Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 209. Sweden Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 210. Poland Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 211. China Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 212. China Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 213. China Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 214. China Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 215. China Diabetic Neuropathic Pain Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 216. China Diabetic Neuropathic Pain Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 217. China Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 218. China Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 219. China Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 220. China Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 221. China Diabetic Neuropathic Pain Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 222. China Diabetic Neuropathic Pain Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 223. Asia Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 224. Asia Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 225. Asia Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 226. Asia Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 227. Asia Diabetic Neuropathic Pain Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 228. Asia Diabetic Neuropathic Pain Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 229. Asia Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 230. Asia Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 231. Asia Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 232. Asia Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 233. Asia Diabetic Neuropathic Pain Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 234. Asia Diabetic Neuropathic Pain Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 235. Asia Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 236. Asia Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 237. Asia Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 238. Asia Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 239. Asia Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 240. Asia Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 241. Asia Diabetic Neuropathic Pain Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 242. Asia Diabetic Neuropathic Pain Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 243. Japan Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 244. South Korea Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 245. India Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 246. Australia Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 247. Taiwan Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 248. Southeast Asia Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 249. SAMEA Diabetic Neuropathic Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 250. SAMEA Diabetic Neuropathic Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 251. SAMEA Diabetic Neuropathic Pain Drug Sales by Type (2021-2026) & (W Units) Table 252. SAMEA Diabetic Neuropathic Pain Drug Sales by Type (2027-2032) & (W Units) Table 253. SAMEA Diabetic Neuropathic Pain Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 254. SAMEA Diabetic Neuropathic Pain Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 255. SAMEA Diabetic Neuropathic Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 256. SAMEA Diabetic Neuropathic Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 257. SAMEA Diabetic Neuropathic Pain Drug Sales by Application (2021-2026) & (W Units) Table 258. SAMEA Diabetic Neuropathic Pain Drug Sales by Application (2027-2032) & (W Units) Table 259. SAMEA Diabetic Neuropathic Pain Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 260. SAMEA Diabetic Neuropathic Pain Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 261. SAMEA Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 262. SAMEA Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 263. SAMEA Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 264. SAMEA Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 265. SAMEA Diabetic Neuropathic Pain Drug Sales by Country (2021-2026) & (W Units) Table 266. SAMEA Diabetic Neuropathic Pain Drug Sales by Country (2027-2032) & (W Units) Table 267. SAMEA Diabetic Neuropathic Pain Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 268. SAMEA Diabetic Neuropathic Pain Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 269. Brazil Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 270. Argentina Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 271. Chile Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 272. Colombia Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 273. Peru Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 274. Saudi Arabia Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 275. Israel Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 276. UAE Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 277. Turkey Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 278. Iran Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 279. Egypt Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Table 280. Key Raw Materials Table 281. Raw Materials Key Suppliers Table 282. Diabetic Neuropathic Pain Drug Distributors List Table 283. Diabetic Neuropathic Pain Drug Customers List Table 284. Research Programs/Design for This Report Table 285. Authors List of This Report Table 286. Secondary Sources Table 287. Primary Sources List of Figures Figure 1. Diabetic Neuropathic Pain Drug Image Figure 2. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Neuropathic Pain Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. AZD-5213 Image Figure 5. E-52862 Image Figure 6. GERPOOI Image Figure 7. GRC-17536 Image Figure 8. Filgrastim Image Figure 9. Duloxetine Hydrochloride DR Image Figure 10. Clonidine Hydrochloride Image Figure 11. Others Image Figure 12. Global Diabetic Neuropathic Pain Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Diabetic Neuropathic Pain Drug Market Size Share 2021 VS 2025 VS 2032 Figure 14. Clinic Image Figure 15. Hospital Image Figure 16. Others Image Figure 17. Global Diabetic Neuropathic Pain Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Diabetic Neuropathic Pain Drug Revenue (2021-2032) & (US$ Million) Figure 19. Global Diabetic Neuropathic Pain Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2021-2032) Figure 22. Global Diabetic Neuropathic Pain Drug Sales (2021-2032) & (W Units) Figure 23. Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 24. Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico Diabetic Neuropathic Pain Drug Sales YoY (2021-2032) & (W Units) Figure 26. Europe Diabetic Neuropathic Pain Drug Sales YoY (2021-2032) & (W Units) Figure 27. China Diabetic Neuropathic Pain Drug Sales YoY (2021-2032) & (W Units) Figure 28. Asia (Excluding China) Diabetic Neuropathic Pain Drug Sales YoY (2021-2032) & (W Units) Figure 29. South America, Middle East and Africa Diabetic Neuropathic Pain Drug Sales YoY (2021-2032) & (W Units) Figure 30. Global Diabetic Neuropathic Pain Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global Diabetic Neuropathic Pain Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global Diabetic Neuropathic Pain Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2021-2032) Figure 36. Global Diabetic Neuropathic Pain Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 37. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 38. Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2021-2032) Figure 39. Global Diabetic Neuropathic Pain Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 40. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2021-2032) Figure 42. Global Diabetic Neuropathic Pain Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 43. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 44. Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2021-2032) Figure 45. North America Diabetic Neuropathic Pain Drug Revenue Share by Type (2021-2032) Figure 46. North America Diabetic Neuropathic Pain Drug Sales Share by Type (2021-2032) Figure 47. North America Diabetic Neuropathic Pain Drug Revenue Share by Application (2021-2032) Figure 48. North America Diabetic Neuropathic Pain Drug Sales Share by Application (2021-2032) Figure 49. North America Diabetic Neuropathic Pain Drug Revenue Share by Country (2021-2032) Figure 50. North America Diabetic Neuropathic Pain Drug Sales Share by Country (2021-2032) Figure 51. Europe Diabetic Neuropathic Pain Drug Revenue Share by Type (2021-2032) Figure 52. Europe Diabetic Neuropathic Pain Drug Sales Share by Type (2021-2032) Figure 53. Europe Diabetic Neuropathic Pain Drug Revenue Share by Application (2021-2032) Figure 54. Europe Diabetic Neuropathic Pain Drug Sales Share by Application (2021-2032) Figure 55. Europe Diabetic Neuropathic Pain Drug Revenue Share by Country (2021-2032) Figure 56. Europe Diabetic Neuropathic Pain Drug Sales Share by Country (2021-2032) Figure 57. China Diabetic Neuropathic Pain Drug Revenue Share by Type (2021-2032) Figure 58. China Diabetic Neuropathic Pain Drug Sales Share by Type (2021-2032) Figure 59. China Diabetic Neuropathic Pain Drug Revenue Share by Application (2021-2032) Figure 60. China Diabetic Neuropathic Pain Drug Sales Share by Application (2021-2032) Figure 61. Asia Diabetic Neuropathic Pain Drug Revenue Share by Type (2021-2032) Figure 62. Asia Diabetic Neuropathic Pain Drug Sales Share by Type (2021-2032) Figure 63. Asia Diabetic Neuropathic Pain Drug Revenue Share by Application (2021-2032) Figure 64. Asia Diabetic Neuropathic Pain Drug Sales Share by Application (2021-2032) Figure 65. Asia Diabetic Neuropathic Pain Drug Revenue Share by Country (2021-2032) Figure 66. Asia Diabetic Neuropathic Pain Drug Sales Share by Country (2021-2032) Figure 67. SAMEA Diabetic Neuropathic Pain Drug Revenue Share by Type (2021-2032) Figure 68. SAMEA Diabetic Neuropathic Pain Drug Sales Share by Type (2021-2032) Figure 69. SAMEA Diabetic Neuropathic Pain Drug Revenue Share by Application (2021-2032) Figure 70. SAMEA Diabetic Neuropathic Pain Drug Sales Share by Application (2021-2032) Figure 71. SAMEA Diabetic Neuropathic Pain Drug Revenue Share by Country (2021-2032) Figure 72. SAMEA Diabetic Neuropathic Pain Drug Sales Share by Country (2021-2032) Figure 73. Diabetic Neuropathic Pain Drug Value Chain Figure 74. Manufacturing Cost Structure Figure 75. Diabetic Neuropathic Pain Drug Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • AZD-5213
  • E-52862
  • GERPOOI
  • GRC-17536
  • Filgrastim
  • Duloxetine Hydrochloride DR
  • Clonidine Hydrochloride
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Eli Lilly and Company
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Theravasc, Inc.
  • Sphaera Pharma Pvt. Ltd.
  • Relmada Therapeutics, Inc.
  • RAPID Pharmaceuticals AG
  • Pharmaleads
  • Novaremed
  • Mertiva AB
  • Lohocla Research Corporation
  • Laboratorios Del Dr. Esteve S.A.
  • Immune Pharmaceuticals Inc.
  • Hydra Biosciences, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Dong-A Socio Group
  • Daiichi Sankyo Company, Limited
  • Boehringer Ingelheim GmbH
  • BioDelivery Sciences International, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Diabetic Neuropathic Pain Drug Market by Type
  3. 1.2.1 Global Diabetic Neuropathic Pain Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 AZD-5213
  5. 1.2.3 E-52862
  6. 1.2.4 GERPOOI
  7. 1.2.5 GRC-17536
  8. 1.2.6 Filgrastim
  9. 1.2.7 Duloxetine Hydrochloride DR
  10. 1.2.8 Clonidine Hydrochloride
  11. 1.2.9 Others
  12. 1.3 Diabetic Neuropathic Pain Drug Market by Application
  13. 1.3.1 Global Diabetic Neuropathic Pain Drug Market Size by Application, 2021 VS 2025 VS 2032
  14. 1.3.2 Clinic
  15. 1.3.3 Hospital
  16. 1.3.4 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Diabetic Neuropathic Pain Drug Market Dynamics
  1. 2.1 Diabetic Neuropathic Pain Drug Industry Trends
  2. 2.2 Diabetic Neuropathic Pain Drug Industry Drivers
  3. 2.3 Diabetic Neuropathic Pain Drug Industry Opportunities and Challenges
  4. 2.4 Diabetic Neuropathic Pain Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Diabetic Neuropathic Pain Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Diabetic Neuropathic Pain Drug Revenue by Region
  3. 3.2.1 Global Diabetic Neuropathic Pain Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Diabetic Neuropathic Pain Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Diabetic Neuropathic Pain Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Diabetic Neuropathic Pain Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Diabetic Neuropathic Pain Drug Sales by Region
  9. 3.4.1 Global Diabetic Neuropathic Pain Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Diabetic Neuropathic Pain Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Diabetic Neuropathic Pain Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Diabetic Neuropathic Pain Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers
  2. 4.1.1 Global Diabetic Neuropathic Pain Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Diabetic Neuropathic Pain Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Diabetic Neuropathic Pain Drug Sales by Manufacturers
  6. 4.2.1 Global Diabetic Neuropathic Pain Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Diabetic Neuropathic Pain Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Diabetic Neuropathic Pain Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Diabetic Neuropathic Pain Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Diabetic Neuropathic Pain Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Diabetic Neuropathic Pain Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Diabetic Neuropathic Pain Drug Manufacturers, Product Type & Application
  13. 4.7 Global Diabetic Neuropathic Pain Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Diabetic Neuropathic Pain Drug Market CR5 and HHI
  16. 4.8.2 2025 Diabetic Neuropathic Pain Drug Tier 1, Tier 2, and Tier 3
5 Diabetic Neuropathic Pain Drug Market by Type
  1. 5.1 Global Diabetic Neuropathic Pain Drug Revenue by Type
  2. 5.1.1 Global Diabetic Neuropathic Pain Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Diabetic Neuropathic Pain Drug Sales by Type
  6. 5.2.1 Global Diabetic Neuropathic Pain Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diabetic Neuropathic Pain Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Diabetic Neuropathic Pain Drug Price by Type
6 Diabetic Neuropathic Pain Drug Market by Application
  1. 6.1 Global Diabetic Neuropathic Pain Drug Revenue by Application
  2. 6.1.1 Global Diabetic Neuropathic Pain Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Diabetic Neuropathic Pain Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Diabetic Neuropathic Pain Drug Sales by Application
  6. 6.2.1 Global Diabetic Neuropathic Pain Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Diabetic Neuropathic Pain Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Diabetic Neuropathic Pain Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Diabetic Neuropathic Pain Drug Price by Application
7 Company Profiles
  1. 7.1 Eli Lilly and Company
  2. 7.1.1 Eli Lilly and Company Company Information
  3. 7.1.2 Eli Lilly and Company Business Overview
  4. 7.1.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly and Company Diabetic Neuropathic Pain Drug Product Portfolio
  6. 7.1.5 Eli Lilly and Company Recent Developments
  7. 7.2 Astellas Pharma Inc.
  8. 7.2.1 Astellas Pharma Inc. Company Information
  9. 7.2.2 Astellas Pharma Inc. Business Overview
  10. 7.2.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  12. 7.2.5 Astellas Pharma Inc. Recent Developments
  13. 7.3 AstraZeneca Plc
  14. 7.3.1 AstraZeneca Plc Company Information
  15. 7.3.2 AstraZeneca Plc Business Overview
  16. 7.3.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Plc Diabetic Neuropathic Pain Drug Product Portfolio
  18. 7.3.5 AstraZeneca Plc Recent Developments
  19. 7.4 Theravasc, Inc.
  20. 7.4.1 Theravasc, Inc. Company Information
  21. 7.4.2 Theravasc, Inc. Business Overview
  22. 7.4.3 Theravasc, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Theravasc, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  24. 7.4.5 Theravasc, Inc. Recent Developments
  25. 7.5 Sphaera Pharma Pvt. Ltd.
  26. 7.5.1 Sphaera Pharma Pvt. Ltd. Company Information
  27. 7.5.2 Sphaera Pharma Pvt. Ltd. Business Overview
  28. 7.5.3 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Sphaera Pharma Pvt. Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  30. 7.5.5 Sphaera Pharma Pvt. Ltd. Recent Developments
  31. 7.6 Relmada Therapeutics, Inc.
  32. 7.6.1 Relmada Therapeutics, Inc. Company Information
  33. 7.6.2 Relmada Therapeutics, Inc. Business Overview
  34. 7.6.3 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Relmada Therapeutics, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  36. 7.6.5 Relmada Therapeutics, Inc. Recent Developments
  37. 7.7 RAPID Pharmaceuticals AG
  38. 7.7.1 RAPID Pharmaceuticals AG Company Information
  39. 7.7.2 RAPID Pharmaceuticals AG Business Overview
  40. 7.7.3 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 RAPID Pharmaceuticals AG Diabetic Neuropathic Pain Drug Product Portfolio
  42. 7.7.5 RAPID Pharmaceuticals AG Recent Developments
  43. 7.8 Pharmaleads
  44. 7.8.1 Pharmaleads Company Information
  45. 7.8.2 Pharmaleads Business Overview
  46. 7.8.3 Pharmaleads Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Pharmaleads Diabetic Neuropathic Pain Drug Product Portfolio
  48. 7.8.5 Pharmaleads Recent Developments
  49. 7.9 Novaremed
  50. 7.9.1 Novaremed Company Information
  51. 7.9.2 Novaremed Business Overview
  52. 7.9.3 Novaremed Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Novaremed Diabetic Neuropathic Pain Drug Product Portfolio
  54. 7.9.5 Novaremed Recent Developments
  55. 7.10 Mertiva AB
  56. 7.10.1 Mertiva AB Company Information
  57. 7.10.2 Mertiva AB Business Overview
  58. 7.10.3 Mertiva AB Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Mertiva AB Diabetic Neuropathic Pain Drug Product Portfolio
  60. 7.10.5 Mertiva AB Recent Developments
  61. 7.11 Lohocla Research Corporation
  62. 7.11.1 Lohocla Research Corporation Company Information
  63. 7.11.2 Lohocla Research Corporation Business Overview
  64. 7.11.3 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Lohocla Research Corporation Diabetic Neuropathic Pain Drug Product Portfolio
  66. 7.11.5 Lohocla Research Corporation Recent Developments
  67. 7.12 Laboratorios Del Dr. Esteve S.A.
  68. 7.12.1 Laboratorios Del Dr. Esteve S.A. Company Information
  69. 7.12.2 Laboratorios Del Dr. Esteve S.A. Business Overview
  70. 7.12.3 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Laboratorios Del Dr. Esteve S.A. Diabetic Neuropathic Pain Drug Product Portfolio
  72. 7.12.5 Laboratorios Del Dr. Esteve S.A. Recent Developments
  73. 7.13 Immune Pharmaceuticals Inc.
  74. 7.13.1 Immune Pharmaceuticals Inc. Company Information
  75. 7.13.2 Immune Pharmaceuticals Inc. Business Overview
  76. 7.13.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  78. 7.13.5 Immune Pharmaceuticals Inc. Recent Developments
  79. 7.14 Hydra Biosciences, Inc.
  80. 7.14.1 Hydra Biosciences, Inc. Company Information
  81. 7.14.2 Hydra Biosciences, Inc. Business Overview
  82. 7.14.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  84. 7.14.5 Hydra Biosciences, Inc. Recent Developments
  85. 7.15 Glenmark Pharmaceuticals Ltd.
  86. 7.15.1 Glenmark Pharmaceuticals Ltd. Company Information
  87. 7.15.2 Glenmark Pharmaceuticals Ltd. Business Overview
  88. 7.15.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Product Portfolio
  90. 7.15.5 Glenmark Pharmaceuticals Ltd. Recent Developments
  91. 7.16 Dong-A Socio Group
  92. 7.16.1 Dong-A Socio Group Company Information
  93. 7.16.2 Dong-A Socio Group Business Overview
  94. 7.16.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Dong-A Socio Group Diabetic Neuropathic Pain Drug Product Portfolio
  96. 7.16.5 Dong-A Socio Group Recent Developments
  97. 7.17 Daiichi Sankyo Company, Limited
  98. 7.17.1 Daiichi Sankyo Company, Limited Company Information
  99. 7.17.2 Daiichi Sankyo Company, Limited Business Overview
  100. 7.17.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Product Portfolio
  102. 7.17.5 Daiichi Sankyo Company, Limited Recent Developments
  103. 7.18 Boehringer Ingelheim GmbH
  104. 7.18.1 Boehringer Ingelheim GmbH Company Information
  105. 7.18.2 Boehringer Ingelheim GmbH Business Overview
  106. 7.18.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Product Portfolio
  108. 7.18.5 Boehringer Ingelheim GmbH Recent Developments
  109. 7.19 BioDelivery Sciences International, Inc.
  110. 7.19.1 BioDelivery Sciences International, Inc. Company Information
  111. 7.19.2 BioDelivery Sciences International, Inc. Business Overview
  112. 7.19.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Product Portfolio
  114. 7.19.5 BioDelivery Sciences International, Inc. Recent Developments
8 North America
  1. 8.1 North America Diabetic Neuropathic Pain Drug Market Size by Type
  2. 8.1.1 North America Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Diabetic Neuropathic Pain Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Diabetic Neuropathic Pain Drug Price by Type (2021-2032)
  5. 8.2 North America Diabetic Neuropathic Pain Drug Market Size by Application
  6. 8.2.1 North America Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Diabetic Neuropathic Pain Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Diabetic Neuropathic Pain Drug Price by Application (2021-2032)
  9. 8.3 North America Diabetic Neuropathic Pain Drug Market Size by Country
  10. 8.3.1 North America Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Diabetic Neuropathic Pain Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Diabetic Neuropathic Pain Drug Market Size by Type
  2. 9.1.1 Europe Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Diabetic Neuropathic Pain Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Diabetic Neuropathic Pain Drug Price by Type (2021-2032)
  5. 9.2 Europe Diabetic Neuropathic Pain Drug Market Size by Application
  6. 9.2.1 Europe Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Diabetic Neuropathic Pain Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Diabetic Neuropathic Pain Drug Price by Application (2021-2032)
  9. 9.3 Europe Diabetic Neuropathic Pain Drug Market Size by Country
  10. 9.3.1 Europe Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Diabetic Neuropathic Pain Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Diabetic Neuropathic Pain Drug Market Size by Type
  2. 10.1.1 China Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Diabetic Neuropathic Pain Drug Sales by Type (2021-2032)
  4. 10.1.3 China Diabetic Neuropathic Pain Drug Price by Type (2021-2032)
  5. 10.2 China Diabetic Neuropathic Pain Drug Market Size by Application
  6. 10.2.1 China Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Diabetic Neuropathic Pain Drug Sales by Application (2021-2032)
  8. 10.2.3 China Diabetic Neuropathic Pain Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Diabetic Neuropathic Pain Drug Market Size by Type
  2. 11.1.1 Asia Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Diabetic Neuropathic Pain Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Diabetic Neuropathic Pain Drug Price by Type (2021-2032)
  5. 11.2 Asia Diabetic Neuropathic Pain Drug Market Size by Application
  6. 11.2.1 Asia Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Diabetic Neuropathic Pain Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Diabetic Neuropathic Pain Drug Price by Application (2021-2032)
  9. 11.3 Asia Diabetic Neuropathic Pain Drug Market Size by Country
  10. 11.3.1 Asia Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Diabetic Neuropathic Pain Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Diabetic Neuropathic Pain Drug Market Size by Type
  2. 12.1.1 SAMEA Diabetic Neuropathic Pain Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Diabetic Neuropathic Pain Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Diabetic Neuropathic Pain Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Diabetic Neuropathic Pain Drug Market Size by Application
  6. 12.2.1 SAMEA Diabetic Neuropathic Pain Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Diabetic Neuropathic Pain Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Diabetic Neuropathic Pain Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Diabetic Neuropathic Pain Drug Market Size by Country
  10. 12.3.1 SAMEA Diabetic Neuropathic Pain Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Diabetic Neuropathic Pain Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Diabetic Neuropathic Pain Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Diabetic Neuropathic Pain Drug Value Chain Analysis
  2. 13.1.1 Diabetic Neuropathic Pain Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Diabetic Neuropathic Pain Drug Production Mode & Process
  6. 13.2 Diabetic Neuropathic Pain Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Diabetic Neuropathic Pain Drug Distributors
  9. 13.2.3 Diabetic Neuropathic Pain Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst